Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-11-07
2006-11-07
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C562S597000, C564S162000
Reexamination Certificate
active
07132456
ABSTRACT:
The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar1, Ar2, Ar3, L1, L2and Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and Related Diseases
REFERENCES:
patent: 3535330 (1970-10-01), Griot
patent: 3928449 (1975-12-01), Griot
patent: 4206072 (1980-06-01), Meyer et al.
patent: 27 52 361 (1979-06-01), None
patent: WO 01/21577 (2001-03-01), None
patent: WO 200121577 (2001-03-01), None
Kutzki, et al., “Development of a potent Bcl-xL antagonist based on alpha-helix mimicry,” Journal of the American Chemical Society, XP002277113, vol. 124, No. 40, pp. 11838-11839 (2002).
Shimizu, et al., “Synthesis and thermal behaviour of 9-substituted 9-thia-10-azaphenanthrenes,” Journal of the Chemical Society, XP002277114, Perkin Transactions 1, No. 7, pp. 1733-1747 (1991).
Wilson, et al., “Substituent parameter analysis of the carbon-13 nuclear magnetic resonance chemical shifts of 4-substituted p-terphenyls,”Journal of Organic Chemistry, XP002277115, vol. 47, No.7, pp. 1184-1188 (1982).
Cramer, et al., “Prospective identification of biologically active structures by topomer shape similarity searching,” Journal of Medicinal Chemistry, XP002149047, vol. 42, No. 19, pp. 3919-3933 (1999).
Carini, et al., “Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl) imidazoles as potent, orally active antihypertensives,” Journal of Medicinal Chemistry, XP000674205, vol. 34, No. 8, pp. 2525-2547 (1991).
Gillig James Ronald
Heinz Lawrence Joseph
Kinnick Michael Dean
Lai Yen-Shi
Morin John Michael
Eli Lilly and Company
Ginah Francis O
Kosack Joseph R.
McKane Joseph K.
LandOfFree
MCH receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MCH receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MCH receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3702716